CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of breast cancer.
  
  OVERVIEW OF ACTIVITY
  Breast cancer remains the most frequently diagnosed cancer in women, and in 2019 in the United States alone the disease will culminate in an estimated 271,270 new cases and 42,260 deaths. Triple-negative breast cancer (TNBC), which accounts for 12% to 17% of all breast cancer cases, typically affects younger women and carries a poor prognosis. However, despite the aggressive nature of TNBC and the lack of current targeted treatments, significant research is providing nuanced therapeutic options. Novel combination approaches in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, and recently published advances in the treatment of metastatic TNBC have shown impressive results with poly(ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. With these many exciting advances, however, many areas of controversy, vexing questions and clinical challenges are emerging. To provide clinicians with therapeutic strategies to address the disparate needs of patients with TNBC, this program features one-on-one discussions with leading breast cancer investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity will assist medical oncologists with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Implement a long-term clinical plan for the management of metastatic TNBC, considering available data and patient and disease characteristics.
  • Review published efficacy and safety data with the approved PARP inhibitors for patients with HER2-negative metastatic breast cancer harboring a BRCA1/2 mutation.
  • Appraise recently presented Phase III data supporting the FDA approval of anti-PD-L1 antibody therapy combined with chemotherapy for patients with newly diagnosed metastatic TNBC.
  • Individualize the selection of treatment for TNBC, including the use of PARP inhibitors for appropriate patients.
  • Develop an understanding of the mechanisms of action of, available data with and potential clinical roles for novel agents and approaches in the clinical care of patients with TNBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: 
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco Medical Center
  UCSF Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seattle Genetics; Paid Travel: Amgen Inc, AstraZeneca Pharmaceuticals LP, Lilly, MacroGenics Inc, Merck, Mylan, Pfizer Inc, Puma Biotechnology Inc.
  
  Melinda Telli, MD
  Associate Professor of Medicine
  Stanford University School of Medicine
  Leader, Breast Oncology Clinical Research Group
  Stanford Cancer Institute
  Stanford, California
  
  Advisory Committee: Aduro Biotech, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Merck; Consulting Agreement: Pfizer Inc; Contracted Research: Biothera Pharmaceuticals Inc, EMD Serono Inc, Genentech, Merck, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro, A GSK Company; Data and Safety Monitoring Board: G1 Therapeutics, Immunomedics Inc. 
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Genomic Health Inc, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seattle Genetics. 
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: November 2019
  Expiration date: November 2020